Download PDF

Other users also viewed these articles

Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study Lidia Serrano Díaz; Carles Iniesta Navalón; Rosa Gómez Espín; Isabel Nicolás De Prado; Enrique Bernal Morell; Lorena Rentero Redondo;
Gastroenterol Hepatol. 2024;47:553-61
Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes Carles Iniesta-Navalón; Lorena Rentero-Redondo; Rosa Gómez-Espín; Manuel Ríos Saorín; Isabel Nicolás de Prado; Juan José Gascón-Cánovas;
Gastroenterol Hepatol. 2025;48:
Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease Lidia Serrano Díaz; Carles Iniesta Navalón; Rosa Gómez Espín; Isabel Nicolás de Prado; Lorena Rentero Redondo;
Gastroenterol Hepatol. 2023;46:504-11